Products

A diversified portfolio of products for high-potential markets

BECAUSE RESULTS MATTER

Therapy-07

PRESCRIPTION

This triple combination therapy works synergistically to encourage optimal hair regrowth in men with androgenic alopecia. Significant regrowth was observed among participants in the clinical trials.

PHASE III CLINICAL TRIALS
2022

Therapy-16

OVER-THE-COUNTER NATURAL PRODUCT

This clinically proven natural formula beats market-leading synthetic formulas and is the perfect choice for men and women looking to prevent hair loss and boost hair growth and thickness.

PROJECTED RELEASE
2021

Some market
numbers

40 years

First drug approved for androgenic alopecia in 40 years.

$2,560

Average spent for hair loss products in the US per patient, per year.

$8.5 B

Hair loss is a US$8.5 billion industry in 2020.

98%

Rogaine and versions of private label Minoxidil control 98% of the topical hair growth market in the U.S.

$12.4 B

Global projected market in 2025.

Recent publications

CORPORATE AND SCIENTIFIC NEWS
                                    Array
(
    [posts_per_page] => 3
    [post_type] => post
    [post_status] => publish
)
                                
READ MORE
Triple Hair
Corporate
Q4 2021 Investors News
READ MORE
Triple Hair
Corporate
BIO Digital Start-Up Stadium Finalist and Financing
READ MORE
Triple Hair
Science
Triple Hair retains Endoceutics